Last $30.53 USD
Change Today -0.37 / -1.20%
Volume 273.6K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:30 AM

Acorda Therapeutics, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:30 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Michael W. Rogers, Chief Financial Officer and Principal Accounting Officer.

Acorda Therapeutics, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Acorda Therapeutics, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.

Acorda Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:05 PM

Acorda Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:05 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Andrew Asa Hindman, Chief Business Development Officer, Ron Cohen, Founder, Chief Executive Officer, President and Director.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Sales Guidance for the Year 2014; Plans to Begin Phase III Clinical Trial

Acorda Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter the company reported GAAP net income of $4.7 million for the second quarter of 2014 or $0.11 per diluted share against $3.9 million, or $0.09 per diluted share a year ago. Non-GAAP net income was $17.7 million, or $0.42 per diluted share. Non-GAAP net income in the same quarter of 2013 was $14.1 million, or $0.34 per diluted share. Total revenues were $97.1 million against $87.1 million reported last year. Operating income was $11 million against $8.7 million a year ago period. Income before income taxes was $10.7 million against $8.2 million reported last year. Net revenue was $87.4 million compared to $77.8 million for the same quarter in 2013. For the six months, the company reported total revenues of $177.6 million compared to $158.9 million reported in the same period a year ago. Net income was $5.4 million or $0.13 per diluted share against net income of $2.8 million or $0.07 per diluted share reported a year ago. Non-GAAP net income was $26.5 million or $0.63 per diluted share against net income of $15.4 million or $0.37 per diluted share reported last year. Operating income was $14.4 million against $6.2 million reported last year. Income before income taxes was $14.2 million against $5.2 million reported a year ago. The company reiterates 2014 AMPYRA net sales guidance of $328 million to $335 million. The company announced that it expects to begin a Phase III clinical trial by the end of the year, studying the use of dalfampridine, which is the active ingredient in AMPYRA, twice-daily to improve walking in people who've experienced a stroke in the past. This formulation was used in its proof-of-concept study, for which the company announced positive results in 2013. But it is working on a new once-daily or QD formulation, which depending on when the company complete development, could potentially be introduced into the Phase III program later.

Acorda Therapeutics, Inc., Q2 2014 Earnings Call, Jul 31, 2014

Acorda Therapeutics, Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $30.53 USD -0.37

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $323.39 USD -3.72
Durect Corp $1.61 USD -0.03
Novartis AG SFr.87.35 CHF -0.25
Teva Pharmaceutical Industries Ltd $52.08 USD +0.62
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 67.6x
Price/Sales 3.5x
Price/Book 2.5x
Price/Cash Flow 66.9x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.